Economic impact of asthma therapy with fluticasone propionate, montelukast, or zafirlukast in a managed care population

Pharmacotherapy

Volumn 22, Issue 2, 2002, Pages 166-174

  Pathak, Dev S ^a   Davis, E Anne ^a   Stanford, Richard H ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; SALMETEROL; ZAFIRLUKAST;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH ECONOMICS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

ACETATES; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; CHILD; COHORT STUDIES; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; QUINOLINES; RETROSPECTIVE STUDIES; TOSYL COMPOUNDS; UNITED STATES;

EID: 0036156334     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.22.3.166.33548     Document Type: Article

References (23)

1. The health economics of asthma and rhinitis. I. Assessing the economic impact
2. The cost of asthma in the emergency department and hospital
3. Global strategy for asthma management
4. Explaining drug spending trends: Does perception match reality?
5. Low-dose inhaled corticosteroids and the prevention of death from asthma
6. Inhaled steroids and the risk of hospitalization for asthma
7. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients
8. Actual use of inhaled corticosteroids and risk of hospitalization: A case-control study
9. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
10. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized, controlled trial
11. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial
12. Fluticasone propionate versus zafirlukast: Effect in patients previously receiving inhaled corticosteroid therapy
13. Smearing estimate: A nonparametric retransformation method
14. Pediatric asthma deaths in Victoria: The mild are at risk
15. Methodological issues in conducting pharmacoeconomic evaluations: Retrospective and claims database studies
16. Randomized, controlled trials, observational studies, and the hierarchy of research designs
17. Randomized trials or observational tribulations
18. Draft consensus development on pharmacoeconomic analysis: A working paper
19. Outcomes analysis in asthma
20. Estimating causal effects from large data sets using propensity scores
21. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables